--A mix-up at a U.S. factory will delay distribution of the Johnson & Johnson Covid-19 vaccine, the New York Times reported.

--The NYT said that workers at the Baltimore plant had accidentally conflated the vaccine's ingredients weeks ago and ruined about 15 million doses of Johnson & Johnson's vaccine.

--The plant is run by Emergent BioSolutions, a manufacturing partner to Johnson & Johnson and AstraZeneca PLC, the NYT said.

--Johnson & Johnson vaccine doses currently being delivered and used nationwide were produced in the Netherlands and are not affected, the NYT reported, adding that all further shipments of the Johnson & Johnson vaccine were supposed to have come from the Baltimore plant and are now in question while the quality control issues are sorted out.

In after-hours trading, Johnson & Johnson shares were down 0.33% at $163.81, while Emergent Solutions' stock was down 4.85% at $88.40.

Full story: https://www.nytimes.com/live/2021/03/31/world/covid-19-coronavirus#johnson-and-johnson-vaccine-mixup

(END) Dow Jones Newswires

March 31, 2021 18:13 ET (22:13 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Emergent Biosolutions Charts.
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Emergent Biosolutions Charts.